IAC Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IAC Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.37B | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $5.24B | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $3.70B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.76B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $2.51B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $2.53B | Feb 17, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.39B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.62B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.92B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $5.24B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.70B | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $848.82M | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | $788.38M | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | $726.36M | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | $684.12M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $670.51M | Feb 17, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($104.03M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($539.90M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $265.94M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($1.17B) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $597.55M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $269.73M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $22.90M | Mar 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($97.42M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($28.68M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($237.78M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($474.77M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($137.07M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($24.37M) | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | ($128.63M) | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | ($107.02M) | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | ($312.34M) | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | ($16.41M) | Feb 17, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.02M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $228.33M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $237.95M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $318.03M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $230.81M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $185.34M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $132.64M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $177.30M | Feb 17, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $354.52M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $189.53M | Feb 28, 2025 |
| FY2024 | Dec 31, 2022 | ($82.79M) | Feb 28, 2025 |
| FY2020 | Dec 31, 2020 | $154.58M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $251.80M | Feb 17, 2021 |
| FY2020 | Dec 31, 2018 | $369.44M | Feb 17, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $15.01M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $93.58M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $139.75M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $90.21M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $60.73M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $95.10M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $54.68M | Feb 17, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.13B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $9.69B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $10.37B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $10.39B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $12.30B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $9.16B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.10B | Feb 17, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.73B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $5.58B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $6.08B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.93B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $7.18B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $6.60B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.54B | Feb 17, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.99B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.14B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $3.03B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.23B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.66B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $1.40B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.48B | Feb 17, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($643.00M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($538.97M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $923.0K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($265.02M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $905.15M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $694.04M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Feb 17, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $960.21M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.38B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $933.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $1.10B | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $2.12B | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $3.37B | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $837.92M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $883.99M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $757.20M | Feb 17, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 20, 2026 |
| FY2024 | Dec 31, 2024 | $1.98B | Feb 28, 2025 |
| FY2023 | Dec 31, 2023 | $2.04B | Feb 29, 2024 |
| FY2022 | Dec 31, 2022 | $2.07B | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $2.10B | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $720.00M | Feb 17, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | (13) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 5 | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | (3) | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 17, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | (13) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 5 | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | (3) | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 17, 2021 |